Phase II trial of HIV vaccines, RG 83894 and IR 103, in antiretroviral-naive patients with HIV infections

Trial Profile

Phase II trial of HIV vaccines, RG 83894 and IR 103, in antiretroviral-naive patients with HIV infections

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs IR 103 (Primary) ; GP120-depleted HIV-1 vaccine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Sponsors Immune Response Corporation; Orchestra Therapeutics
  • Most Recent Events

    • 18 Jul 2007 Status changed from in progress to discontinued.
    • 19 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top